Products with Inhibitors bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN6474 | Songoramine |
| 1. Songoramine(10 uM) demonstrates significant hERG K+ channel inhibition. | |
| BCN6477 | Marein |
| 1. Marein shows neuroprotective effect on PC12 cell damage induced by methylglyoxal, which is due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway, indicates that marein may be a potent compound for preventing/counteracting diabetic encephalopathy. 2. Marein shows antioxidant activity. 3. Marein can improve insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. 4. Marein shows Histone deacetylase enzymes (HDACs) inhibitory activity and it also can inhibit TNFα-induced NF-κB activation. | |
| BCN6479 | Desoxyrhapontigenin |
| 1. Desoxyrhapontigenin shows significant monoamine oxidase inhibitory activities with the IC50 value of 11.5 ± 1.1 uM. 2. Desoxyrhapontigenin up-regulates Nrf2-mediated heme oxygenase-1(HO-1) expression in macrophages and inflammatory lung injury, and HO-1 is an important anti-inflammatory, antioxidative and cytoprotective enzyme. 3. Desoxyrhapontigenin shows anti-inflammatory properties by the inhibition of iNOS and COX-2 expression via the down-regulation of the MAPK signaling pathways and the inhibition of NF-κB and Akt activation. 4. Desoxyrhapontigenin and desoxyrhaponticin have significant hypoglycemic and antioxidant effects. | |
| BCN6480 | Quercetagetin-7-O-glucoside |
| 1. Quercetagetin-7-O-glucoside, quercetagetin, quercetagetin 3'-methyl ether 7-O-glucoside, patuletin, and patuletin 7-O-glucoside are "yellow flavonols", and it was shown that the flower colors of three yellow-flowered species are due to these compounds. 2. Quercetagetin-7-O-glucoside, a potent inhibitor of beta-glucuronidase and lysozyme release, shows anti-inflammatory activity, can significantly inhibit arachidonic acid release from membranes. | |
| BCN6483 | Epimedokoreanin B |
| 1. Epimedokoreanin B can significantly inhibit the formation of both N (ε) -(carboxymethyl)lysine (CML) and N (ω) -(carboxymethyl)arginine (CMA), it may prevent clinical complications of diabetes by inhibiting advanced glycation end-products (AGEs). 2. Epimedokoreanin B shows scavenge the DPPH radical activity. 3. Epimedokoreanin B can inhibit the proliferation of MCF-7 and HepG2 in dose-dependant manner. | |
